glp-1 market size 2024 Drug Market: the rapid growth of the diabetes and obesity drugs GLP-1 Analogues Market Size, Share

Based on studies suggesting people taking a glucagon-like peptide-1 (GLP-1) could be less likely to develop Alzheimers, Novo Nordisk set up two large trials of its drug, semaglutide sold as the popular diabetes and obesity drugs Ozempic and Wegovy

That means compounded versions of semaglutide the active ingredient in Novo Nordisk's Ozempic and Rybelsus for diabetes and obesity therapy Wegovy are already in the market

As a result, the nervous system that controls the sweat glands is constantly overstimulated

Bacteriostatic water, which is commonly used in compounded formulations, contains a preservative (typically 0.9% benzyl alcohol) that inhibits bacterial growth

#GLP1 #PeptideTherapy #CravingControl #InsulinSupport #PrivatePractice To view or add a comment, sign in Common Side Effects of GLP1 Therapies GLP1 receptor agonists (like Ozempic, Wegovy, etc.) can offer significant benefits in weight and metabolic controlbut they come with possible side effects, including nausea, diarrhea, vomiting, constipation, and mild abdominal discomfort

Our programs feature daily check-ins from our expert health coaches, as well as weekly and monthly progress monitoring check-ins to help you stay on track and maintain success